Septerna's Q2 Loss Widens to $35.6M Amid R&D Ramp-Up

Ticker: SEPN · Form: 10-Q · Filed: Aug 11, 2025 · CIK: 1984086

Sentiment: bearish

Topics: Biotechnology, Clinical Stage, Net Loss, R&D Expenses, Cash Burn, Drug Development, GPCR

Related Tickers: SEPN

TL;DR

**Septerna is burning cash faster than ever, so buckle up for more losses as they chase that elusive drug approval.**

AI Summary

Septerna, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company remains in the clinical development stage. The net loss for the three months ended June 30, 2025, was $35.6 million, a 20.3% increase from the $29.6 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $70.1 million, up 19.8% from $58.5 million in the first half of 2024. Research and development expenses increased to $29.8 million for the three months ended June 30, 2025, from $24.7 million in the prior year, driven by increased clinical trial activities and personnel costs. General and administrative expenses also rose to $6.0 million for the three months ended June 30, 2025, compared to $5.0 million in 2024, primarily due to higher professional fees and stock-based compensation. The company's strategic outlook focuses on advancing its GPCR-targeted pipeline, with significant R&D investment expected to continue. Key risks include the inherent uncertainties of drug development and the need for substantial future funding.

Why It Matters

Septerna's increasing net losses and R&D expenses highlight the significant capital burn typical for early-stage biotech firms, which is crucial for investors to monitor as it directly impacts runway. The company's continued investment in its GPCR-targeted pipeline suggests a commitment to long-term value creation, but also signals a prolonged period without revenue. For employees, this indicates job security tied to successful clinical progression and future funding rounds. In a competitive landscape, Septerna's ability to advance its pipeline efficiently will determine its market position against larger pharmaceutical companies with deeper pockets.

Risk Assessment

Risk Level: high — Septerna reported a net loss of $35.6 million for Q2 2025 and $70.1 million for the first six months of 2025, with no revenue. This significant and increasing cash burn, coupled with the inherent uncertainties of drug development, indicates a high financial risk. The company's future success is entirely dependent on the successful development and commercialization of its product candidates, which is a long and uncertain process.

Analyst Insight

Investors should closely monitor Septerna's cash position and the progress of its clinical trials. Given the high burn rate and lack of revenue, new investors should exercise extreme caution, while existing investors should assess their risk tolerance and consider the potential for future dilutive financing rounds.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$35.6M
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
0.0%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$00.0%

Key Numbers

Key Players & Entities

FAQ

What were Septerna's revenues for the second quarter of 2025?

Septerna, Inc. reported no revenue for the three months ended June 30, 2025, consistent with the prior year period, as the company is in the clinical development stage.

How much was Septerna's net loss in Q2 2025?

Septerna's net loss for the three months ended June 30, 2025, was $35.6 million, an increase from the $29.6 million net loss reported in the same period of 2024.

What drove the increase in Septerna's research and development expenses?

Research and development expenses for Septerna increased to $29.8 million for the three months ended June 30, 2025, from $24.7 million in the prior year, primarily due to increased clinical trial activities and higher personnel costs.

What is Septerna's strategic outlook regarding its drug pipeline?

Septerna's strategic outlook focuses on advancing its GPCR-targeted pipeline, indicating continued significant investment in research and development to progress its drug candidates through clinical trials.

What are the main risks for Septerna investors?

The main risks for Septerna investors include the inherent uncertainties and high costs of drug development, the company's significant and increasing net losses, and the potential need for substantial future funding, which could be dilutive.

How did Septerna's general and administrative expenses change in Q2 2025?

General and administrative expenses for Septerna increased to $6.0 million for the three months ended June 30, 2025, compared to $5.0 million in the same period of 2024, mainly due to higher professional fees and stock-based compensation.

Why does Septerna have no revenue?

Septerna has no revenue because it is a clinical-stage biotechnology company focused on research and development, meaning its product candidates are still in development and have not yet received regulatory approval for commercialization.

What is the year-to-date net loss for Septerna as of June 30, 2025?

For the six months ended June 30, 2025, Septerna reported a net loss of $70.1 million, which is an increase from the $58.5 million net loss during the first half of 2024.

What impact do Septerna's financial results have on its employees?

Septerna's financial results, particularly the increasing R&D investment, suggest continued focus on pipeline development, which generally supports employment in the short term, but long-term job security is tied to successful clinical outcomes and sustained funding.

What is the significance of Septerna's focus on GPCR-targeted therapies?

Septerna's focus on GPCR-targeted therapies indicates its specialization in a significant class of drug targets, aiming to develop novel treatments for various diseases, which could offer substantial market potential if successful in clinical trials.

Risk Factors

Industry Context

The pharmaceutical preparations industry, particularly the clinical development segment, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies like Septerna, Inc. focus on specific therapeutic areas, often targeting novel mechanisms like GPCRs, to differentiate their pipelines. The competitive landscape is intense, with success heavily reliant on scientific innovation, clinical trial outcomes, and securing substantial funding.

Regulatory Implications

Septerna, Inc. operates within a highly regulated environment. The company's progress is contingent on successful navigation of regulatory pathways, including rigorous clinical trials and eventual FDA approval. Any setbacks in regulatory processes, such as delays in trial approvals or rejections, pose significant risks to the company's development timeline and financial viability.

What Investors Should Do

  1. Monitor cash burn and future funding rounds.
  2. Evaluate progress in clinical trials.
  3. Assess management's execution of R&D strategy.

Key Dates

Glossary

Clinical Development Stage
A phase in a drug's lifecycle where it is being tested in human subjects to assess its safety and efficacy. (Explains why Septerna, Inc. has no revenue and incurs significant R&D expenses.)
GPCR-Targeted Pipeline
A portfolio of drug candidates designed to interact with G protein-coupled receptors, a common class of cell surface receptors involved in many physiological processes. (Highlights Septerna's core therapeutic focus and the area of its R&D investment.)
Net Loss
The total expenses incurred by a company exceed its total revenues over a specific period. (Indicates the company's profitability, which is negative as it is in the development stage. The increase in net loss signifies higher operational costs.)
Research and Development (R&D) Expenses
Costs incurred by a company in the process of developing new products or services, including clinical trials and scientific research. (A major expense category for clinical-stage biotechs like Septerna, reflecting investment in future growth.)
General and Administrative (G&A) Expenses
Costs associated with the overall management and operation of a business, not directly tied to product development or sales. (Represents overhead costs, which are increasing for Septerna due to professional fees and stock-based compensation.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Septerna, Inc. continues to report no revenue, consistent with its clinical development stage. However, the net loss has widened significantly, with Q2 2025 net loss at $35.6 million, a 20.3% increase year-over-year. This is driven by a substantial rise in R&D expenses to $29.8 million, up from $24.7 million in Q2 2024, due to increased clinical trial activities and personnel. G&A expenses also saw an increase. No new significant risks were highlighted, but the existing risks related to funding and development uncertainties are amplified by the increased burn rate.

Filing Stats: 4,438 words · 18 min read · ~15 pages · Grade level 19.4 · Accepted 2025-08-11 16:11:42

Key Financial Figures

Filing Documents

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Balance Sheets 1 Condensed Statements of Operations and Comprehensive Loss 2 Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) 3 Condensed Statements of Cash Flows 4 Notes to Unaudited Condensed Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II. OTHER INFORMATION 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 34

Signatures

Signatures 35 We own various U.S. federal trademark applications and unregistered trademarks, including our company name and logo, that we use in connection with the operation of our business. This Quarterly Report on Form 10-Q (this "Quarterly Report") includes our trademarks and trade names which are protected under applicable intellectual property laws and are our property. This Quarterly Report also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. From time to time, we may use our website as well as social media, including our X (formerly known as Twitter) account at Septerna_Inc and our LinkedIn account at https://www.linkedin.com/company/septernainc/ to distribute material information about us and for complying with our disclosure obligations under Regulation FD. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.Septerna.com . Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our social media are not incorporated into, and does not form a part of, this Quarterly Report. i SPECIAL

—FIN ANCIAL INFORMATION

PART I—FIN ANCIAL INFORMATION Ite m 1. Condensed Financial Statements. SEPTERNA, INC. Condensed B alance Sheets (In thousands, except for share and per share data) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 189,311 $ 238,196 Marketable securities 137,250 112,727 Accounts receivable 151 171 Prepaid expenses and other current assets 7,429 5,730 Total current assets 334,141 356,824 Marketable securities, non-current 52,633 69,866 Property and equipment, net 4,688 5,090 Operating lease right-of-use assets 22,564 23,602 Restricted cash 905 905 Other non-current assets 300 267 Total assets $ 415,231 $ 456,554 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 6,544 $ 3,200 Accrued expenses and other current liabilities 6,557 7,798 Operating lease liabilities, current 2,026 1,851 Total current liabilities 15,127 12,849 Operating lease liabilities, non-current 22,545 23,625 Other non-current liabilities 2 33 Total liabilities 37,674 36,507 Commitments and contingencies (Note 5) Stockholders' equity: Preferred stock, $ 0.001 par value per share; 10,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value per share, 500,000,000 shares authorized at June 30, 2025 and December 31, 2024; 44,567,891 and 44,422,505 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively; 341,721 and 576,829 shares subject to repurchase as of June 30, 2025 and December 31, 2024, respectively 45 44 Additional paid-in capital 542,024 538,321 Accumulated other comprehensive income 176 56 Accumulated deficit ( 164,688 ) ( 118,374 ) Total stockholders' equity 377,557 420,047 Total liabi

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing